Quick Answer
UNITED THERAPEUTICS Corp reported Operating Income Loss of $1.49 billion for the year ending 2025.
- UNITED THERAPEUTICS Corp showed an increase of +8.4% in Operating Income Loss from 2024 to 2025.
- This data is from UNITED THERAPEUTICS Corp's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), UNITED THERAPEUTICS Corp's Operating Income Loss has grown by 1,918.9%.
- Historical annual values: Fiscal year 2025: $1.49 billion | Fiscal year 2024: $1.38 billion | Fiscal year 2023: $1.18 billion | Fiscal year 2022: $979.70 million | Fiscal year 2021: $555.90 million | Fiscal year 2020: $593.60 million | Fiscal year 2019: -$187.60 million | Fiscal year 2018: $805.40 million | Fiscal year 2017: $814.90 million | Fiscal year 2016: $1.06 billion | Fiscal year 2015: $699.00 million | Fiscal year 2014: $538.80 million | Fiscal year 2013: $292.50 million | Fiscal year 2012: $421.65 million | Fiscal year 2011: $317.78 million | Fiscal year 2010: $171.31 million | Fiscal year 2009: $25.76 million | Fiscal year 2008: -$82.06 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: